Cargando…
Effect of EPA on Hsp90 and GRα protein expression in multiple myeloma drug-resistant cells
BACKGROUND: Approximately 20% of MM patients harbor glucocorticoid (GC) resistance and are not responsive to therapeutic effect. Chaperoneheat-shock proteins Hsp90 is needed for ligand docking, The imbalance of Hsp90/GRα (glucocorticoid receptor α) may be an important cause of GC resistance. Recent...
Autores principales: | Wu, Shenghao, Chen, Yuemiao, Wang, Xueshuang, Weng, Shanshan, Zhou, Wenjin, Liu, Zhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487534/ https://www.ncbi.nlm.nih.gov/pubmed/34600510 http://dx.doi.org/10.1186/s12885-021-08804-6 |
Ejemplares similares
-
METTL3 affects FLT3-ITD+ acute myeloid leukemia by mediating autophagy by regulating PSMA3-AS1 stability
por: Wu, Shenghao, et al.
Publicado: (2023) -
Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
por: Suzuki, Rikio, et al.
Publicado: (2014) -
Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015) -
The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep
por: Chang, Cheng, et al.
Publicado: (2023) -
The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
por: Usmani, Saad Z, et al.
Publicado: (2010)